<DOC>
	<DOCNO>NCT02732951</DOCNO>
	<brief_summary>This proof mechanism trial explore effect BI 1026706 central retinal thickness evaluate safety tolerability BI 1026706 administer orally 12 week patient mild vision impairment due center-involved DME</brief_summary>
	<brief_title>Safety Effect Central Retinal Thickness BI 1026706 Patients With Diabetic Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<criteria>Inclusion criterion : Patients 18 year age old Male patient female patient nonchildbearing potential Diagnosis Diabetes mellitus type 1 type 2 Retinal thickening due Diabetic macular edema ( DME ) involve center macula study eye confirm Investigator clinical exam Centerinvolved DME confirm SpectralDomain Optical Coherence Tomography ( SDOCT ) central subfield thickness ( CSFT ) least 300 Âµm study eye screening , confirmed Central Reading Centre Best correct visual acuity ETDRS ( Early Treatment Diabetic Retinopathy Study ) letter score study eye 84 , least 70 screen Further inclusion criterion apply Exclusion criterion : Macular edema consider due cause DME study eye Additional eye disease study eye , opinion Investigator , might affect macular edema could compromise alter visual acuity course trial Anterior segment vitreous abnormality study eye would compromise adequate assessment best correct visual acuity adequate examination posterior pole Intraocular surgery study eye within 4 month prior randomization plan intraocular surgery , include cataract , study period Proliferative diabetic retinopathy iris neovascularisation study eye Aphakia study eye Any indication require immediate treatment treatment expect study eye antiVascular Endothelial Growth Factor ( VEGF ) laser photocoagulation period , per Investigator 's judgment History prior laser photocoagulation surgical , intravitreal peribulbar treatment study eye within 4 month prior randomization , either DME ocular condition DME History fluocinolone acetonide intravitreal implant study eye Application intraocular corticosteroid study eye within 2 year prior randomization phakic eye 9 month pseudophakic eye History topical steroid nonsteroidal antiinflammatory drug ( NSAID ) treatment study eye within 30 day prior randomization Systemic antiVEGF proVEGF treatment within 4 month prior randomization Initiation intensive insulin treatment ( multiple daily injection pump ) within 3 month prior randomization plan next 4 month Change oral antidiabetic medication within 3 month prior randomization Patients clinically relevant abnormal screen haematology , blood chemistry , urinalysis Renal impairment estimate creatinine clearance &lt; 30 mL/min ( calculate CockcroftGault equation ) Myocardial infarction unstable angina pectoris within 3 month randomization Uncontrolled arterial hypertension define single measurement systolic &gt; 180 mmHg , two consecutive measurement systolic &gt; 160 mmHg , diastolic &gt; 100mmHg optimal medical regimen Further exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>